{"id":40643,"date":"2025-10-10T20:35:00","date_gmt":"2025-10-10T20:35:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4794867_AE94867_0"},"modified":"2025-10-10T20:35:00","modified_gmt":"2025-10-10T20:35:00","slug":"circulation-publishes-6-month-outcomes-from-first-in-human-vcas-trial-of-fieldforce-pulsed-field-ablation-system-82-freedom-from-vt-vf-recurrence-and-98-reduction-in-burden","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=40643","title":{"rendered":"Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce\u2122 Pulsed Field Ablation System: 82% Freedom from VT\/VF Recurrence and 98% Reduction in Burden"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Findings presented at the International VT Symposium and published simultaneously in Circulation.<\/p>\n

CARDIFF-BY-THE-SEA, Calif.<\/span> and PHILADELPHIA<\/span><\/span>, Oct. 11, 2025<\/span><\/span> \/PRNewswire\/ — Field Medical, Inc. today announced that Circulation<\/a><\/i> has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS<\/a>), the first-in-human evaluation of its FieldForce\u2122 Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).<\/p>\n

\"The<\/a>
The FieldForce\u2122 Ablation System by Field Medical: This next-generation PFA system is designed for transmural lesion creation, offering a novel approach to VT ablation.<\/span> <\/div>\n

Results at Six Months
<\/b>VCAS is a prospective, multicenter feasibility trial evaluating the safety and performance of the FieldForce Ablation System in patients with VT. Unlike conventional approaches, the system delivers a proprietary high-voltage, short-pulse waveform designed to penetrate dense scar tissue while minimizing thermal injury.<\/p>\n

Key Findings:<\/b><\/p>\n